June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Spectroscopic Analysis of Meibum in Individuals With and Without Meibomian Gland Dysfunction
Author Affiliations & Notes
  • Saumya Nagar
    Allergan, an AbbVie company, California, United States
  • Sandeep Kumar
    Allergan, an AbbVie company, California, United States
  • Cathy Zhao
    Allergan, an AbbVie company, California, United States
  • Kugen K. Naidoo
    University of Louisville, Louisville, Kentucky, United States
  • Layla Ajouz
    Allergan, an AbbVie company, California, United States
  • Michael R Robinson
    Allergan, an AbbVie company, California, United States
  • Douglas Borchman
    University of Louisville, Louisville, Kentucky, United States
  • Footnotes
    Commercial Relationships   Saumya Nagar AbbVie Inc., Code E (Employment); Sandeep Kumar AbbVie Inc., Code C (Consultant/Contractor); Cathy Zhao AbbVie Inc., Code E (Employment); Kugen Naidoo None; Layla Ajouz AbbVie Inc., Code E (Employment); Michael Robinson AbbVie Inc., Code E (Employment); Douglas Borchman None
  • Footnotes
    Support  Funded by AbbVie
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4014. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Saumya Nagar, Sandeep Kumar, Cathy Zhao, Kugen K. Naidoo, Layla Ajouz, Michael R Robinson, Douglas Borchman; Spectroscopic Analysis of Meibum in Individuals With and Without Meibomian Gland Dysfunction. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4014.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : There is limited information on the relationship between meibum composition and disease severity of meibomian gland dysfunction (MGD). The purpose of this study was to analyze the molecular components of meibum collected from individuals with no MGD, mild-to-moderate MGD, and severe MGD.

Methods : Adults with and without MGD were enrolled in a prospective, multicenter, exploratory clinical trial (ClinicalTrials.gov Identifier: NCT01979887). MGD disease status and severity were evaluated and defined based on maximum meibum quality scores, Schirmer test results, and Subject Ocular Symptom Questionnaire responses. Based on this, participants were grouped into non-MGD (group A), mild-to-moderate MGD (group B), and severe MGD (group C). The cholesteryl ester / wax ester molar ratio (RCE/WE) and aldehyde / wax ester molar ratio for meibum samples from the groups was measured using 1H-NMR spectroscopy by individuals masked to the group assignments.

Results : A total of 69 meibum samples were included in the analysis, 24 each from the non-MGD and mild-to-moderate MGD groups and 21 from the severe MGD group. The average molar ratio of cholesteryl ester to wax ester was 51% lower (P = 0.038) for group B compared with group A, 52% lower (P = 0.16) for group C compared with group B, and 76% lower (P = 0.002) for group C compared with group A. The average molar ratio of aldehydes to wax ester was 277% higher (P = 0.07) for group B compared with group A, 190% higher (P = 0.003) for group C compared with group B, and 992% higher (P < 0.001) for group C compared with group A.

Conclusions : These findings demonstrate that RCE/WE may have a direct impact on MGD pathophysiology and ocular surface lipid homeostasis, with lowest ratios apparent in the severe MGD group. To the best of our knowledge, this is the first report of higher aldehyde to wax ester molar ratios reported in the meibum secretions of individuals with severe MGD compared with mild/moderate MGD and no MGD. Aside from poor lipid quality in individuals who have MGD leading to tear film instability and evaporative tear loss, the aldehydes in the abnormal meibum secretions mix into the tears and can potentially contribute to the chronic ocular surface inflammation that has been associated with dry eye disease. The findings from this biochemical analysis of meibum can potentially help identify targets for MGD treatment.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×